Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from CSL ( (AU:CSL) ) is now available.
CSL Limited has announced an update on its ongoing share buy-back program, revealing that a total of 2,773,525 ordinary fully paid securities have been repurchased before the previous day, with an additional 46,950 securities bought back on the previous day. This buy-back initiative is part of CSL’s strategy to manage its capital structure effectively, potentially enhancing shareholder value and reinforcing its market position.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$256.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and delivery of innovative biotherapies and influenza vaccines. The company is a global leader in plasma-derived therapies and operates in various markets worldwide, providing essential medicines to patients with rare and serious conditions.
YTD Price Performance: -33.39%
Average Trading Volume: 1,150,052
Technical Sentiment Signal: Sell
Current Market Cap: A$89.23B
Learn more about CSL stock on TipRanks’ Stock Analysis page.